Sodium Phenylbutyrate; Taurursodiol Patent Expiration
Sodium Phenylbutyrate; Taurursodiol is Used for the treatment of Amyotrophic Lateral Sclerosis (ALS) in adults. It was first introduced by Amylyx Pharmaceuticals Inc
Sodium Phenylbutyrate; Taurursodiol Patents
Given below is the list of patents protecting Sodium Phenylbutyrate; Taurursodiol, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Relyvrio | US11583542 | Compositions of bile acids and phenylbutyrate compounds | Jul 27, 2040 | Amylyx |
| Relyvrio | US10251896 | Compositions for improving cell viability and methods of use thereof | Dec 24, 2033 | Amylyx |
| Relyvrio | US10857162 | Compositions for improving cell viability and methods of use thereof | Dec 24, 2033 | Amylyx |
| Relyvrio | US11071742 | Compositions for improving cell viability and methods of use thereof | Dec 24, 2033 | Amylyx |
| Relyvrio | US9872865 | Compositions for improving cell viability and methods of use thereof | Dec 24, 2033 | Amylyx |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Sodium Phenylbutyrate; Taurursodiol's patents.
Latest Legal Activities on Sodium Phenylbutyrate; Taurursodiol's Patents
Given below is the list recent legal activities going on the following patents of Sodium Phenylbutyrate; Taurursodiol.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Letter from FDA or Dept of Agriculture re PTE application | 29 Aug, 2025 | US10251896 |
| Letter from FDA or Dept of Agriculture re PTE application | 29 Aug, 2025 | US9872865 |
| Letter from FDA or Dept of Agriculture re PTE application | 29 Aug, 2025 | US11071742 |
| Letter from FDA or Dept of Agriculture re PTE application | 29 Aug, 2025 | US10857162 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 09 Jul, 2025 | US9872865 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 Jan, 2025 | US11071742 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 21 Jan, 2025 | US11071742 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 14 Aug, 2024 | US10857162 |
| Surcharge for late Payment, Small Entity | 14 Aug, 2024 | US10857162 |
| Maintenance Fee Reminder Mailed | 29 Jul, 2024 | US10857162 |
Sodium Phenylbutyrate; Taurursodiol's Family Patents
